Wugen Enters into License Agreement with Washington University for its CAR-T Therapy Technologies
Shots:
- Wugen to get exclusive & IPR rights for CAR-T Technologies developed by Washington University
- The focus of the agreement is to develop and commercialize novel CAR-T therapies to treat blood cancer
- The novel CAR-T therapy platform including fratricide-resistant “off-the-shelf” system- targeting CD7+ T cell malignancies
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
